Intanza® 15μg intradermal seasonal influenza vaccine: In older adults (aged ≥60 Years)

Drugs and Aging

Volumn 27, Issue 7, 2010, Pages 597-605

  Duggan, Sean T ^a   Plosker, Greg L ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Adis Drug Profiles; Influenza virus vaccines, therapeutic use

Indexed keywords

INFLUENZA VACCINE; INTANZA; UNCLASSIFIED DRUG;

DRUG COMPARISON; DRUG TOLERABILITY; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; PRIORITY JOURNAL; REVIEW; SEASONAL INFLUENZA; AGED; ARTICLE; COMPARATIVE STUDY; IMMUNOLOGY; INFLUENZA; INFLUENZA VIRUS B; INTRADERMAL DRUG ADMINISTRATION; MICROINJECTION; MIDDLE AGED;

AGED; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA B VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; INJECTIONS, INTRADERMAL; MICROINJECTIONS; MIDDLE AGED;

EID: 77954170464     PISSN: 1170229X     EISSN: 11791969     Source Type: Journal    
DOI: 10.2165/11203880-000000000-00000     Document Type: Review

References (32)

1. Stephenson I, Nicholson KG. Influenza: vaccination and treatment. Eur Respir J 2001 Jun; 17 (6): 1282-1293
2. Thompson WW, Shay DK, Weintraub E, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 2003 Jan 8; 289 (2): 179-186 (Pubitemid 36068705)
3. Weinberger B, Herndler-Brandstetter D, Schwanninger A, et al. Biology of immune responses to vaccines in elderly persons. Clin Infect Dis 2008 Apr 1; 46 (7): 1078-1084
4. Stephenson I, Clark TW, Pareek M. Antiviral treatment and prevention of seasonal influenza: a comparative review of recommendations in the European Union. J Clin Virol 2008 Jul; 42 (3): 244-248
5. Blank PR, Schwenkglenks M, Szucs TD. Influenza vaccination coverage rates in five European countries during season 2006/07 and trends over six consecutive seasons. BMC Public Health 2008; 8: 272
6. Mereckiene J, Cotter S, Weber JT, et al. Low coverage of seasonal influenza vaccination in the elderly in many European countries. Euro Surveill 2008 Oct 9; 13 (41)
7. Fiore AE, Shay DK, Broder K, et al. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2008. MMWR Morb Mortal Wkly Rep 2008 Aug 8; (RR-7): 1-60
8. WHO. Resolution of the World Health Assembly (WHA 56.19). Prevention and control of influenza pandemics and annual epidemics. WHA 10th Plenary Meeting; 2003 May 28
9. Council of the European Union. Council recommendation of 22 December 2009 on seasonal influenza vaccination (text with EEA relevance) [2009/1019/EU]. Official J European Union 2009; 348: 71
10. Goodwin K, Viboud C, Simonsen L. Antibody response to influenza vaccination in the elderly: a quantitative review. Vaccine 2006 Feb 20; 24 (8): 1159-1169
11. Aw D, Silva AB, Palmer DB. Immunosenescence: emerging challenges for an ageing population. Immunology 2007 Apr; 120 (4): 435-446
12. Aspinall R, Del Giudice G, Effros RB, et al. Challenges for vaccination in the elderly. Immun Age 2007; 4 (9)
13. Nicolas JF, Guy B. Intradermal, epidermal and transcutaneous vaccination: from immunology to clinical practice. Expert Rev Vaccines 2008 Oct; 7 (8): 1201-1214
14. Lambert PH, Laurent PE. Intradermal vaccine delivery: will new delivery systems transform vaccine administration? Vaccine 2008 Jun 19; 26 (26): 3197-3208
15. Kenney RT, Frech SA, Muenz LR, et al. Dose sparing with intradermal injection of influenza vaccine. N Engl J Med 2004 Nov 25; 351 (22): 2295-2301
16. European Medicines Agency. Assessment report for Intanza (influenza vaccine [split virion, inactivated]) [online]. Available from URL: http://www.ema.europa.eu/humandocs/PDFs/ EPAR/intanza/H-957-en6.pdf [Accessed 2009 Feb 8]
17. Alarcon JB, Hartley AW, Harvey NG, et al. Preclinical evaluation of microneedle technology for intradermal delivery of influenza vaccines. Clin Vaccine Immunol 2007 Apr; 14 (4): 375-381
18. Belshe RB, Newman FK, Cannon J, et al. Serum antibody responses after intradermal vaccination against influenza. N Engl J Med 2004 Nov 25; 351 (22): 2286-2294
19. Belshe RB, Newman FK, Wilkins K, et al. Comparative immunogenicity of trivalent influenza vaccine administered by intradermal or intramuscular route in healthy adults. Vaccine 2007 Sep 17; 25 (37-38): 6755-6763
20. Briggs DJ, Banzhoff A, Nicolay U, et al. Antibody response of patients after postexposure rabies vaccination with small intradermal doses of purified chick embryo cell vaccine or purified Vero cell rabies vaccine. BullWorld Health Organ 2000; 78 (5): 693-698
21. Fabrizi F, Andrulli S, Bacchini G, et al. Intradermal versus intramuscular hepatitis B re-vaccination in non-responsive chronic dialysis patients: a prospective randomized study with cost-effectiveness evaluation. Nephrol Dial Transplant 1997 Jun; 12 (6): 1204-1211
22. Laurent PE, Bonnet S, Alchas P, et al. Evaluation of the clinical performance of a new intradermal vaccine administration technique and associated delivery system. Vaccine 2007; 25 (52): 8833-8842
23. European Medicines Agency. IDflu 15 microgram/strain suspension for injection (nfluenza vaccine [split virion, inactivated]) [online]. Available from URL: http://www. ema.europa.eu/humandocs/PDFs/EPAR/idflu/H-966-PI-en. pdf [Accessed 2010 Apr 8]
24. Laurent A, Mistretta F, Bottigioli D, et al. Echographic measurement of skin thickness in adults by high frequency ultrasound to assess the appropriate microneedle length for intradermal delivery of vaccines. Vaccine 2007 Aug 21; 25 (34): 6423-6430
25. Holland D, Booy R, De Looze F, et al. Intradermal influenza vaccine administered using a new microinjection system produces superior immunogenicity in elderly adults: a randomized controlled trial. J Infect Dis 2008 Sep 1; 198 (5): 650-658
26. Arnou R, Icardi G,De Decker M, et al. Intradermal influenza vaccine for older adults: a randomized controlled multicenter phase III study. Vaccine 2009 Dec 9; 27 (52): 7304-7312
27. Van Damme P, Arnou R, Kafeja F, et al. Evaluation of noninferiority of intradermal versus adjuvanted seasonal influenza vaccine using two serological techniques: a randomised comparative study. BMC Infect Dis 2010; 10: 134
28. European Medicines Agency. Intanza 15 microgram/strain suspension for injection (influenza vaccine [split virion, inactivated]): summary of product characteristics [online]. Available from URL: http://www.ema.europa.eu/human docs/PDFs/EPAR/intanza/emea-combined-h957en.pdf [Accessed 2010 Feb 8]
29. European Committee for Proprietary Medicinal Products (CPMP). Note for guidance on harmonisation of requirements for influenza vaccines [online]. Available from URL: http://www.ema.europa.eu/pdfs/human/bwp/021496en.pdf [Accessed 2010 Feb 12]
30. Reygrobellet C, Viala-Danten M, Meunier J, et al. Perception and acceptance of intradermal influenza vaccination: patient reported outcomes from phase 3 clinical trials. Hum Vaccin 2010; 6 (4): 336-345
31. Arnou R, Eavis P, De Juanes Pardo JR, et al. Immunogenicity, large scale safety and lot consistency of an intradermal influenza vaccine in adults aged 18-60 years: randomized, controlled, phase III trial. Hum Vaccin 2010; 6 (4): 346-354
32. Chevat C, Viala-Danten M, Dias-Barbosa C, et al. Development and psychometric validation of a self-administered questionnaire assessing the acceptance of influenza vaccination: the Vaccinees' Perception of Injection (VAPI) questionnaire. Health Qual Life Outcomes 2009; 7: 21